A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 66,021 shares at $22.58 ($1.4M) on 2025-09-30, disclosed to the SEC on 2025-10-02.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 3,837 | $0 | 0.0% |
| 2 | $22.58 | 31,092 | $702K | 50.0% |
| 3 | $22.58 | 31,092 | $702K | 50.0% |
| Total | $21.27 avg | 66,021 | $1.4M | 100% |
| Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |
| APLS | SELL | 2024-03-20 | $2.1M | — | Filing → |